Table 1 Selected Characteristics of 13 studies included in meta-analysis
Source | Country | Sample size, (cases/noncases) | Age (mean), y | Female, % | Tools for stressful events | |
|---|---|---|---|---|---|---|
Gray et al., 1985 [15] | UK | 50/50 | 43.1 | 76.0 | Semi-structured interview | |
Winsa et al., 1991 [11] | Sweden | 208/372 | 40.2 | 82.0 | Self-rating questionnaires (LES) | |
Sonino et al., 1993 [12] | Italy | 70/70 | 39.2 | 82.9 | Semi-structured interview (PIRLE) | |
Kung et al., 1995 [13] | China | 95/95 | 33.1 | 84.2 | Self-rating questionnaires (LES) | |
Radosavljević et al., 1996 [14] | Serbia | 100/100 | 40.6 | 93 | Semi-structured interview (PIRLE) | |
Yoshiuchi et al., 1998 [16] | Japan | 228/228 | 38.4 | 79.8 | Self-rating questionnaires (HRLES) | |
Matos-Santos et al., 2001 [23] | Portugal | 31/31 | 38.4 | 71 | Self-rating questionnaires (LES) | |
Pintor et al., 2003 [24] | Philippines | 224/224 | 37.1 | 86.6 | Self-rating questionnaires (LES) | |
Topcu et al., 2012 [25] | Turkey | 45/37 | 40.9 | 73.3 | Self-rating questionnaires (LES) | |
Yoshichi et al., 1998 [26] | Japan | 155/75a | 38.4 | 79.1 | Self-rating questionnaires (HRLES) | |
Fukao et al., 2003 [27] | Japan | 41/28a | 41.0 | 94.2 | Self-rating questionnaires (NSI) | |
Chen et al., 2012 [28] | China | 129/148a | 37.9 | 72.9 | Self-rating questionnaires (LES) | |
Vita et al., 2014 [29] | Italy | 43/15a | 35.4 | 62.1 | Semi-structured interview | |
Study design | Outcome | Diagnosis | Quality | |||
Case-control | GD | Chemical tests, diagnosis by physician | 7 | |||
Case-control | GD | Clinical signs, raised thyroid hormone, suppressed TSH, thyroid-related antibodies | 9 | |||
Case-control | GD | Clinical features, increased thyroxine, suppressed TSH, thyroid-related antibodies | 8 | |||
Case-control | GD | Clinical features, thyroid scan, increased thyroxine, suppressed TSH | 7 | |||
Case-control | GD | Clinical signs, increased thyroxine, suppressed TSH, thyroid scintigraphy | 8 | |||
Case-control | GD | Clinical features, increased thyroxine, decreased TSH, thyroid scintigraphy, thyroid-related antibodies | 7 | |||
Case-control | GD | Clinical criteria, increased thyroxine, suppressed TSH, thyroid-related antibodies | 8 | |||
Case-control | GD | Clinical signs, raised thyroxine, decreased TSH, thyroid-related antibodies | 6 | |||
Case-control | GD | Thyroxine, TSH suppression, thyroid-related antibodies, thyroid USG | 7 | |||
Prospective cohort study | Drug efficacy | Concentrations of FT4, FT3, TSH, and TBII | 7 | |||
Prospective cohort study | Drug efficacy | serum-free thyroxine,TSH concentrations | 8 | |||
Prospective cohort study | Drug efficacy | Thyroxine, TSH concentrations | 8 | |||
Prospective cohort study | Drug efficacy | suppressed levels of TSH, levels of FT3 and/or FT4. | 9 | |||